Taysha Gene Therapies, Inc. (TSHA)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Taysha Gene Therapies, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 4.16 | 4.45 | 4.14 | 4.33 | 3,182,537 |
| Nov 5, 2026 | 4.38 | 4.40 | 4.00 | 4.09 | 6,742,979 |
| Nov 4, 2026 | 4.08 | 4.38 | 4.00 | 4.36 | 4,033,565 |
| Nov 3, 2026 | 4.05 | 4.17 | 3.92 | 4.09 | 1,728,943 |
| Nov 2, 2026 | 4.30 | 4.30 | 3.95 | 4.00 | 2,007,822 |
| Oct 30, 2026 | 4.18 | 4.25 | 4.07 | 4.13 | 1,501,141 |
| Oct 29, 2026 | 4.22 | 4.47 | 4.14 | 4.22 | 2,057,816 |
| Oct 28, 2026 | 4.24 | 4.28 | 4.12 | 4.23 | 3,402,738 |
| Oct 27, 2026 | 4.03 | 4.28 | 3.97 | 4.25 | 2,824,718 |
| Oct 26, 2026 | 3.98 | 4.09 | 3.95 | 4.01 | 1,819,776 |
| Oct 23, 2026 | 3.95 | 3.98 | 3.75 | 3.96 | 2,592,942 |
| Oct 22, 2026 | 4.07 | 4.17 | 3.94 | 4.00 | 3,105,125 |
| Oct 21, 2026 | 4.15 | 4.26 | 4.05 | 4.12 | 3,511,184 |
| Oct 20, 2026 | 3.95 | 4.20 | 3.89 | 4.11 | 10,925,868 |
| Oct 19, 2026 | 3.66 | 3.96 | 3.65 | 3.94 | 5,817,013 |
| Oct 16, 2026 | 3.73 | 3.75 | 3.60 | 3.62 | 2,751,861 |
| Oct 15, 2026 | 3.53 | 3.79 | 3.50 | 3.73 | 4,685,719 |
| Oct 14, 2026 | 3.51 | 3.71 | 3.46 | 3.51 | 4,342,800 |
| Oct 13, 2026 | 4.09 | 4.13 | 3.55 | 3.58 | 6,117,216 |
| Oct 12, 2026 | 4.46 | 4.56 | 4.13 | 4.14 | 4,214,238 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Nagendran Sukumar | President and Head of R&D | Sale | 200.0K | $1.25M | Jul 10, 2026 |
 Stalfort John A III | Director | Grant/Award | 21.3K | -- | Jun 1, 2026 |
 Sepp-Lorenzino Laura | Director | Grant/Award | 42.7K | -- | Jun 1, 2026 |
 Donenberg Phillip B. | Director | Grant/Award | 42.7K | -- | Jun 1, 2026 |
| Stalfort John A III | Director | Grant/Award | 42.7K | -- | Jun 1, 2026 |
 Long Alison S | Director | Grant/Award | 42.7K | -- | Jun 1, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Avoro Capital Advisors LLC | 23.9M | 7.3% | 13F |
RA CAPITAL MANAGEMENT, L.P. | 23.6M | 7.2% | 13F |
GOLDMAN SACHS GROUP INC | 22.7M | 7.0% | 13F |
BlackRock, Inc. | 20.7M | 6.4% | 13F |
RTW Investments, LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 20.7M | 6.3% | 13G |
Vestal Point Capital, LP | 19.4M | 6.0% | 13F |
Vestal Point Capital, LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 18.0M | 5.5% | 13G |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2026 | 17.9M | 5.5% | 13G |
MORGAN STANLEY | 16.5M | 5.1% | 13F |
Morgan Stanley · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 16.2M | 5.0% | 13G |
Insiders
- Nagendran SukumarPresident and Head of R&D
- Stalfort John A IIIDirector
- Sepp-Lorenzino LauraDirector
- Donenberg Phillip B.Director
- Long Alison SDirector
- Alam KamranCHIEF FINANCIAL OFFICER
- Nolan Sean P.Chief Executive Officer
- Manning Paul B10% Owner
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors.
Its core mission is to tackle inherited diseases affecting the central nervous system (CNS).
The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
based on 325.83M shares outstanding
US30d Avg
3.87M
60d Avg
4.28M
90d Avg
3.63M